A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

European Journal of Preventive Cardiology

Volumn 21, Issue 4, 2014, Pages 434-441

  Smink, P A ^a   Hoekman, J ^a   Grobbee, D E ^b   Eijkemans, Mjc ^b   Parving, H H ^c,d   Persson, F ^e   Ibsen, H ^f   Lindholm, L ^g   Wachtell, K ^h   De Zeeuw, D ^a   Heerspink, Hj Lambers ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e STENO DIABETES CENTER   (Denmark)

^f HOLBÆK HOSPITAL   (Denmark)

^g UMEÅ UNIVERSITY   (Sweden)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

biomarkers; cardiovascular disease; direct renin inhibition; nephropathy; Type 2 diabetes

Indexed keywords

ALBUMIN; ALISKIREN; BIOLOGICAL MARKER; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; IRBESARTAN; LOSARTAN; PLACEBO; POTASSIUM ION; URIC ACID; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

ADULT; AGED; ALBUMIN TO CREATININE RATIO; ALBUMINURIA; ANALYTICAL PARAMETERS; ARTICLE; ATTRIBUTABLE RISK; BODY MASS; CARDIO RENAL RISK; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARAMETER RESPONSE EFFICACY SCORE; PHARMACOLOGICAL PARAMETERS; PLACEBO EFFECT; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TIME; TREATMENT DURATION; URIC ACID BLOOD LEVEL; ALGORITHM; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DECISION SUPPORT SYSTEM; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TREATMENT OUTCOME;

AGED; ALGORITHMS; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896465696     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487313481754     Document Type: Article

References (15)

1. Lambers Heerspink HJ, de Zeeuw D. Dual RAS therapy not on target, but fully alive. Nephron Clin Pract. 2010 ; 116: c137 - c142
2. Miao Y, Lambers Heerspink HJ, Parving HH, et al. Short-term prediction of long-term renoprotective treatment effect: The advantage of a multiple biomarker-based efficacy score. American Society Nephrology 2011, Philadelphia, USA.
3. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints: Rationale and study design. Nephrol Dial Transplant. 2009 ; 24: 1663-1671
4. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study-Rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 2000 ; 1: 328-335
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860
6. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 ; 359: 1004-1010
7. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 ; 358: 2433-2446
8. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004 ; 65: 2309-2320
9. Miao Y, Dobre D, Heerspink HJ, et al. Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011 ; 54: 44-50
10. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet. 2007 ; 370: 221-229
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 ; 338: b1665 - b1665
12. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int. 2003 ; 63: 1499-1507
13. European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study EMA/CHMP/989693/2011.
14. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 ; 367: 2204-2213
15. Parving HH, Brenner BM, McMurray JJ, et al. (on behalf of the ALTITUDE investigators). Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. 2012 ; 13: 387-393